<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377609</url>
  </required_header>
  <id_info>
    <org_study_id>PMR-EC-1215</org_study_id>
    <secondary_id>2013-002086-19</secondary_id>
    <nct_id>NCT02377609</nct_id>
  </id_info>
  <brief_title>To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks</brief_title>
  <official_title>Cross-validation of the Finger Prick Dried Blood Spot Assay Method With the Established Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to define the relationship between tacrolimus
      concentrations determined from the finger prick DBS (Dry Blood Spot) method and those
      determined from blood samples collected by venepuncture in transplant recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a bioanalytical assay method cross-validation study using blood samples donated
      by up to 100 liver and 100 kidney transplant patients. Subjects who will be attending a
      routine outpatient follow-up visit will be asked to provide 3 whole blood venepuncture
      samples (each sample = 3 mL blood) and 3 finger prick DBS blood samples at predose and at 1
      and 3 hours postdose. All subjects will be discharged from the study and clinical site at 3
      hours postdose. Subjects will derive no benefit from the blood collection procedures and will
      be paid a predetermined stipend for participating in the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DBS method not be validated against the standard of care venepuncture method due to quality of
    blood sample and variable tacrolimus extraction
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Cross-validate the dried blood spot (DBS) method by defining the relationship between tacrolimus concentrations determined via DBS method, with those determined using the established and validated whole blood method</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare estimated area under the curve (AUC) values of the DBS and whole blood assay methods using a Bayesian model</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Validation</condition>
  <condition>Dried Blood Spot</condition>
  <condition>Transplant Patients</condition>
  <arm_group>
    <arm_group_label>Kidney or Liver Transplant Patients</arm_group_label>
    <description>adult kidney or liver Advagraf® (tacrolimus) recipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>Kidney or Liver Transplant Patients</arm_group_label>
    <other_name>Advagraf</other_name>
    <other_name>FK506E</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Dried blood spot and blood collected by venepuncture
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stable kidney or liver transplant recipient receiving Advagraf® (tacrolimus) therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable adult transplant recipients aged ≥ 18 years maintained on a once daily
             Advagraf® based immunosuppressive regimen for the prophylaxis of kidney or liver
             allograft rejection.

        Exclusion Criteria:

          -  Subjects who are still participating in another clinical study (e.g. attending follow
             up visits) or who have participated in a clinical study involving administration of an
             investigational drug (new chemical entity) in the past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 7</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 1</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 2</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Blood Spot (DBS)</keyword>
  <keyword>Validation</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Bioanalytical assay method cross-validation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

